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VIEWPOINT

Randomized Trials Are Needed for
Transcatheter Mitral Valve Replacement
Jason H. Rogers, MD,a Paul Sorajja, MD,b Vinod H. Thourani, MD,c Rahul Prakash Sharma, MD,d
Bassem Chehab, MD,e Jennifer Cowger, MD, MS,f David Heimansohn, MD,g Vinay Badhwar, MD,h
Mayra Guerrero, MD,i Gorav Ailawadi, MDj

ABSTRACT
Transcatheter mitral valve replacement (TMVR) is a new therapy for treating symptomatic mitral regurgitation (MR) and
stenosis. The proposed beneﬁt of TMVR is the predictable, complete elimination of MR, which is less certain with
transcatheter repair technologies such as TEER (transcatheter edge-to-edge repair). The potential beneﬁt of MR elimination with TMVR needs to be rigorously evaluated against its risks which include relative procedural invasiveness, need
for anticoagulation, and chronic structural valve deterioration. Randomized controlled trials (RCTs) are a powerful
method for evaluating the safety and effectiveness of TMVR against current standard of care transcatheter therapies,
such as TEER. RCTs not only help with the assessment of beneﬁts and risks, but also with policies for determining
operator or institutional requirements, resource utilization, and reimbursement. In this paper, the authors provide recommendations and considerations for designing pivotal RCTs for ﬁrst-in-class TMVR devices.
(J Am Coll Cardiol Intv 2021;14:2039–2046) © 2021 by the American College of Cardiology Foundation.
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Randomized controlled trials (RCTs) provide a

(TMVR) is a rapidly evolving therapy for the

mitral

valve

vehicle for evaluating the safety and effectiveness of

treatment of symptomatic mitral regurgita-

novel pharmacologic, surgical, or transcatheter ther-

tion (MR) and mitral stenosis (MS). Numerous TMVR

apies against the existing standard of care and can

devices are currently under investigation (1). A major

also help determine operator or institutional re-

potential beneﬁt of TMVR is the predictable, com-

quirements, resource utilization, and reimbursement.

plete elimination of MR, which is less certain with

RCTs to evaluate ﬁrst-in-class technologies such as

transcatheter edge-to-edge repair (TEER). The poten-

TMVR must consider the mitral pathologies and

tial beneﬁt of MR elimination with TMVR needs to be

existing treatment options to deﬁne appropriate

evaluated against its risks, including relative proce-

control groups. We herein review considerations and

dural invasiveness, need for anticoagulation, and

proposed recommendations for designing pivotal

long-term structural valve deterioration.

RCTs for TMVR devices, incorporating the recently
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ABBREVIATIONS

updated U.S. guidelines for the treatment of

AND ACRONYMS

valvular heart disease (2).

GDMT = guideline-directed

Valve Disease
Etiology of MR/MS

MITRAL VALVE PATHOLOGIES AND

medical therapy

AVAILABLE TREATMENT MODALITIES

LV = left ventricular
MAC = mitral annular

T A B L E 1 Treatment Options for Patients With Mitral

Available Treatment Options

Severe primary MR
(Carpentier class IIA)

 Surgical mitral valve repair if
candidate for surgery (Class 1
recommendation)
 TEER if high or prohibitive risk
(Class 2A recommendation)
 Surgical mitral valve replacement if
unrepairable valve

Severe secondary MR
(Carpentier class IIIB)

 GDMT (Class 1 recommendation)
 TEER if subjects are symptomatic
despite GDMT and meet commercial TEER indications (Class 2A)
 Surgical mitral valve replacement
or repair may be considered if patients are symptomatic despite
GDMT (Class 2B)

Severe MR due to severe
MAC (Carpentier
class IIIA)

 Unmet clinical need; surgery is high
risk; patients may be managed with
medical therapy with limited
efﬁcacy

Rheumatic severe MS

 PMBC (Class 1)
 Surgical mitral valve replacement
or repair if patient is not suitable
for PMBC (Class 1)

The complex mitral valve apparatus consists

calciﬁcation

of 2 leaﬂets (anterior and posterior) in an

MR = mitral regurgitation

anatomical continuum with the left ventricle

MS = mitral stenosis

via chordae tendineae and circumferentially

NYHA = New York Heart

to the atrioventricular groove via a ﬁbrous,

Association

saddle-shaped annulus. Anatomical abnor-

PMR = primary mitral
regurgitation

malities of the mitral valve apparatus or

RCT = randomized controlled

related cardiac anatomy such as the left

trial

atrium or left ventricle can result in MR, MS,

RMVD = rheumatic mitral valve

or both. Both MR and MS signiﬁcantly affect

disease

normal cardiovascular function and, when

SMR = secondary mitral

symptomatic, require treatment. MR exists in

regurgitation

2 basic forms: primary mitral regurgitation

TEER = transcatheter edge-to-

(PMR) (due to a primary abnormality of the

edge repair

mitral valve apparatus) and secondary mitral

TMVR = transcatheter mitral

regurgitation (SMR) (due to left ventricular

valve replacement

[LV] dysfunction and annular dilatation).
For patients with symptomatic PMR (Carpentier
class II, increased leaﬂet motion) mitral valve surgery
has a Class 1B recommendation, with surgical mitral
valve repair preferred over mitral valve replacement.

Nonrheumatic calciﬁc severe  Surgical valve intervention should
MS due to
be considered only after extensive
severe MAC
discussion of the high procedural
risk and the individual patient’s
preference and values (Class 2B)
GDMT ¼ guideline-directed medical therapy; MAC ¼ mitral annular calciﬁcation;
MR ¼ mitral regurgitation; MS ¼ mitral stenosis; PMBC ¼ percutaneous mitral
balloon commissurotomy; TEER ¼ transcatheter edge-to-edge repair.

The guidelines speciﬁcally state that mitral valve
replacement should not be performed in patients
with PMR when leaﬂet pathology is limited to the
posterior leaﬂet (the most common form of PMR),

surgery is performed concomitant with coronary ar-

unless repair has been attempted and failed. For pa-

tery bypass grafting, mitral replacement is generally

tients with PMR who are at high or prohibitive risk for

preferred

mitral

repair).

valve

surgery,

TEER

has

a

Class

2A

over

restrictive

annuloplasty

(mitral

MR may also occur as a consequence of restricted

recommendation.
For patients with chronic SMR (Carpentier class

leaﬂet motion in both systole and diastole (Carpentier

IIIb, restricted leaﬂet motion in systole alone) and

class IIIa) because of either rheumatic mitral valve

heart

fraction,

disease (RMVD) or severe mitral annular calciﬁcation

guideline-directed medical therapy (GDMT) has a

(MAC). These conditions may also result in severe MS.

Class 1 recommendation. On the basis of the results of

The primary treatment option for many patients with

COAPT (Cardiovascular Outcomes Assessment of the

RMVD is percutaneous mitral balloon commissur-

MitraClip Percutaneous Therapy for Heart Failure

otomy. Mitral valve surgery (repair, replacement, or

Patients With Functional Mitral Regurgitation Trial),

commissurotomy) is recommended as a Class 1 indi-

TEER was recently added as a Class 2A recommen-

cation for patients with RMVD who are not candidates

dation for patients who have chronic severe SMR

for percutaneous mitral balloon commissurotomy or

related to LV dysfunction, persistent symptoms (New

who require other concomitant cardiac procedures.

York Heart Association [NYHA] functional class II, III,

Although RMVD is the most common form of MS and

or IV) while on optimal GDMT for heart failure,

more prevalent in developing nations, MS and MR

appropriate leaﬂet anatomy, LV ejection fraction be-

due to severe MAC are increasingly prevalent in

tween 20% and 50%, LV end-systolic diameter #

elderly patients in developed countries. Treatment

70 mm, and pulmonary artery systolic pressure #

options for patients with severe MAC are limited

70 mm Hg (3). Mitral valve surgery for isolated SMR is

because the extent of calciﬁcation alters the anatomy

only recommended as a Class 2B indication for pa-

of the annulus, the leaﬂet tips, as well as left atrial

tients who are symptomatic despite GDMT; when

and LV compliance, often resulting in an increased

failure

with

reduced

ejection
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F I G U R E 1 Trial Design Approaches for New Transcatheter Mitral Technologies in Patients With Primary and Secondary MR

(A) Flow diagram outlining trial design options for primary mitral regurgitation (MR). *Patients with primary MR who are not candidates for
surgery or transcatheter edge-to-edge repair therapy (TEER) who do not have other treatment options can be studied in a single-arm trial
concurrent with a randomized controlled trial (RCT). A concurrent RCT is preferable so as to characterize the safety and effectiveness of the
investigational device against standard of care therapy. (B) Flow diagram outlining trial design options for secondary MR. Note that either
TEER or guideline-directed medical therapy (GDMT) may be considered as standard of care for patients with secondary MR depending on
anatomy. P.G. ¼ performance goal.

transvalvular gradient. The prognosis of patients with

CLINICAL TRIAL CONSIDERATIONS FOR

severe MAC is quite poor without intervention (4),

NOVEL TMVR DEVICES

but surgical intervention requires extensive debridement of the calcium, which is technically challenging

The design of clinical trials for novel TMVR devices

and increases operative risk (5,6). Guidelines support

must take into account the complexity and heterog-

intervention for severe MS as only a Class 2B indica-

enous nature of mitral valve pathologies and avail-

tion for severely symptomatic patients (NYHA func-

able treatment options. Table 1 shows the available

tional class III or IV) when the MS is attributable to

treatment options for patients with mitral valve dis-

MAC. The high risk of available treatment options for

ease. Although there can be beneﬁts associated with

patients with severe MAC and the relative lack of data

complete MR elimination from valve replacement

on the treatment of patients with severe MAC with

versus valve repair, the risks of valve replacement

MR represents a signiﬁcant unmet clinical need.

must be weighed against other available therapies.
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T A B L E 2 Pros and Cons Associated With Potential Control Groups for TMVR Trials

Surgery

GDMT

TEER (MitraClip)

Pros
The comparative precedent for TMVR is
surgical replacement in patients with secondary/mixed MR

GDMT is the standard of care for patients
who are not suitable for surgery or TEER
with the MitraClip (particularly for secondary MR)

TMVR offers a less invasive approach for
mitral valve replacement

The MitraClip is the preferred standard
of care for selected patients with secondary MR
There are unanswered questions on the
beneﬁts and risks (Table 1) of TMVR vs
TEER, which an RCT will answer

Cons
Surgery is a Class 2B indication for treatment
of isolated secondary MR

COAPT demonstrated that correcting secondary MR with TEER in patients with
heart failure provides signiﬁcant clinical
beneﬁt

Surgery for isolated secondary MR is performed rarely: w4.3% of all surgical
procedures

Physicians will offer available therapies
(eg, TEER) to symptomatic patients on
GDMT, and patients will prefer TEER
rather than remaining on GDMT alone

TMVR and TEER have different mechanisms of action, different impact on MR
elimination, and different safety proﬁles, making randomization important
but challenging

With release of the COAPT results and subsequent approval of the MitraClip for secondary MR, reimbursement, and ultimately
guideline support, TEER with the MitraClip is
the preferred standard of care for appropriate patients with secondary MR
Conclusion
Conducting an enrollable RCT vs surgery is not
feasible

Implementing an RCT with GDMT alone as a
control is not an enrollable trial given
proven beneﬁt of TEER (MitraClip)

Compared with surgery and GDMT,
randomization to TEER (MitraClip) is the
only practical and feasible randomization
pathway for TMVR

COAPT ¼ Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation Trial; RCT ¼ randomized controlled trial;
TMVR ¼ transcatheter mitral valve replacement; other abbreviations as in Table 1.

As treatment options are available for both MR and
MS, novel transcatheter mitral valve interventional

approaches for new transcatheter mitral technologies
in patients with PMR and SMR.

devices (repair or replacement) should be evaluated

For novel TMVR technologies, standard-of-care

in RCTs to adequately assess safety and effectiveness

treatment that serves as an appropriate control

against current standard of care. For transcatheter

group is rapidly evolving. A summary of strengths

technologies targeted to patients with PMR, RCTs

and limitations of potential control groups can be

must be considered against surgical mitral valve

found in Table 2. For PMR, either surgery or TEER

repair for surgical candidates or TEER for patients

may serve as the control group depending upon sur-

who are at high risk for surgical mortality. For trans-

gical candidacy. TEER in particular is now being

catheter technologies targeted to patients with severe

routinely used in patients with PMR who are at pro-

SMR, randomized clinical trials may be considered

hibitive or high surgical risk and in patients with SMR

against GDMT, TEER, or surgery depending on patient

who are symptomatic despite GDMT. With the recent

anatomy or surgical candidacy. Single-arm trials for

guideline inclusion of TEER as Class 2A and Medicare

patients with an unmet clinical need (eg, those with

coverage for both PMR and SMR, TEER has become

severe MAC or with PMR who are not candidates for

the de facto standard of care today for many high- or

surgery or TEER) may be considered but are most

prohibitive-risk patients with PMR or SMR.

meaningful if performed within an overall construct

As the only commercially available transcatheter

that includes an RCT to best interpret the safety and

therapy for both PMR and SMR, TEER serves as a

effectiveness of novel ﬁrst-in-class transcatheter de-

logical control group for TMVR RCTs. The broad

vices against the standard of care. Single-arm trials

applicability and availability of TEER and improved

may also exhibit a tendency toward “enrollment

outcomes with newer generation devices for different

creep,” as randomizable patients may be enrolled in

subsets of patients with MR poses challenges as well

the single arm if a concomitant RCT arm is not

as opportunities to conduct RCTs (Figure 2A). For

available. Figures 1A and 1B show trial design

patients who are not suitable for TEER (see the
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F I G U R E 2 Trial Design Options for a First-in-Class TMVR Device

(A) Option 1: trial design for a ﬁrst-in-class transcatheter mitral valve replacement (TMVR) device with an RCT arm against TEER. *Patients must be high or prohibitive
risk for surgery. †There is an unmet clinical need for patients with severe mitral annular calciﬁcation (MAC). As such, there is no appropriate control group for this
patient cohort, and these patients may be studied in a single-arm study as long as it is concurrent with an RCT against TEER or GDMT (B). ††A single-arm trial in
non-TEER patients may be considered in this construct, as the safety and effectiveness of the TMVR design will be evaluated in an RCT against TEER. If the RCT arm
was not present, this group must be randomized to GDMT (B). (B) Option 2: trial design for a ﬁrst-in-class TMVR device with an RCT arm against GDMT. Abbreviations
as in Figure 2.
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T A B L E 3 Potential Beneﬁts and Risks That Are Evaluable in Randomized Clinical Trials of

TMVR Versus TEER

Kansas City Cardiomyopathy Questionnaire score)
may be considered as a component of a composite
primary endpoint depending upon the trial’s intent

Transapical TMVR

Transfemoral TEER

Complete, predictable, and durable
elimination of MR

Transfemoral approach to repair the
mitral valve with expedited patient
recovery

either superiority or noninferiority depending upon

Strong early safety proﬁle

Excellent safety proﬁle

may consider noninferiority designs, and transseptal

Agnostic to MR pathophysiology

Established outcomes and operator
familiarity with >100,000 global
implantations

devices may be designed to demonstrate superior-

Early data that are beneﬁcial for left
ventricular remodeling

No requirement for anticoagulation

Beneﬁts

but should not be used in isolation. Trials with TEER
as a control group can be designed to demonstrate
the device features (eg, transapical TMVR devices

ity). Results from such trials must also be used to
deﬁne anatomies for which TMVR may be more
suitable than TEER and vice versa. Trials against

Supported by randomized clinical trial
data
Risks

GDMT must be designed to demonstrate superiority.
Effect size for superiority trials of TMVR versus
TEER may be based on the incremental impact of MR

Implanted via left thoracotomy

Only applicable to anatomies conducive
to edge-to-edge repair

Large-bore apical delivery system

Results in smaller mitral valve area

heart failure hospitalization. Effect size for superi-

Requires anticoagulation for at least the
short term

Risk for residual or recurrent MR

ority trials of TMVR versus GDMT may be based on

New operator and site requirements for
performance and delivery

Outcomes may vary with operator
experience

elimination over MR reduction on mortality and

the results observed in COAPT. Noninferiority trials

Anatomic exclusions to therapy
(ie, LVOT obstruction)
LVOT ¼ left ventricular outﬂow tract; other abbreviations as in Tables 1 and 2.

must be designed to ensure there is no violation of
the “constancy assumption” (designing trials similar
to the past trial that demonstrated effectiveness of
the TEER control compared with GDMT placebo) and
must demonstrate that outcomes with the TMVR
device are not worse than TEER by a clinically signiﬁcant margin (10).

section on trial execution considerations), RCTs

Secondary endpoints should typically include

against GDMT should be considered, as a signiﬁcant

those pertaining to safety (eg, composite of major

majority of patients who qualify for TMVR will have

adverse events, stroke, bleeding, myocardial infarc-

SMR, for which GDMT is standard of care (Figure 2B).

tion), device effectiveness (eg, MR severity), mea-

RCTs against surgery may also be considered (for

sures of success (technical success, device success,

patients who are surgical candidates), but such trials

patient success), LV dimensions (eg, LV end-diastolic

will be difﬁcult to enroll, as surgery is rarely per-

and end-systolic volumes), quality of life (eg, Kansas

formed for isolated SMR (7). Single-arm trials may be

City

appropriate provided the trial structure includes a

functional capacity (eg, 6-minute walk distance,

concurrent RCT (eg, TEER in Figure 2A, GDMT in

NYHA functional class). Secondary endpoints must be

Figure 2B).

adjusted for multiple testing, and all other endpoints

Cardiomyopathy

Questionnaire

score),

and

should be evaluated descriptively.

ENDPOINT CONSIDERATIONS
TRIAL EXECUTION CONSIDERATIONS
The Mitral Valve Academic Research Consortium
guidance documents elegantly outline endpoints

Trial oversight at multiple junctures for pivotal TMVR

that should be considered for transcatheter mitral

trials is critical. An independent clinical events com-

valve trials (8,9). Depending upon the trial’s objec-

mittee and a data monitoring committee should be

tives, primary, secondary, and descriptive endpoints

used to adjudicate adverse events and monitor the

may be chosen from the options provided within the

safety of trial participants. Imaging core laboratories

Mitral Valve Academic Research Consortium docu-

are recommended for the anatomical and functional

ments. As patients with untreated MR are at high

pathophysiological assessment of the mitral valve

risk for mortality and progressive heart failure

derived

symptomatology, the primary endpoint for TMVR

tomographic imaging studies.

from

echocardiographic

and

computed

trials should include endpoints that are related to

Perhaps the most critical component for oversight

heart failure (ie, mortality and/or heart failure hos-

of TMVR trials is evaluation of surgical candidacy,

pitalizations). As noted in the Mitral Valve Academic

GDMT, and TEER suitability. Such oversight needs to

Research Consortium document, quality of life (eg,

be provided by a subject eligibility committee, which
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must be composed of representatives from cardiac

risk for thromboembolic complications. The larger

surgery, heart failure, and interventional cardiology.

stent frames and additional prosthetic material for

The role of the mitral heart team surgeon is to ensure

TMVR systems in comparison with surgical valves

that the patient is an appropriate candidate for sur-

require consideration of antithrombotic therapy with

gery (if the trial is randomizing to surgery) or not a

warfarin for at least 6 months postimplantation, with

candidate for surgery (if the trial is in a patient pop-

a target international normalized ratio of 2.5 to 3.5 to

ulation not suitable for surgery). If the trial is

minimize the risk for thromboembolic complications.

randomizing against GDMT, the heart failure cardi-

Although the speciﬁc anticoagulation requirements

ologist needs to ensure that the patient is optimized

(international normalized ratio range and duration)

on GDMT. The recent favorable data from the use

may change with expanded experience and are indi-

angiotensin receptor blockers/neprilysin inhibitors

vidualized to the device features, patients who

and sodium-glucose cotransporter-2 inhibitors in pa-

cannot tolerate anticoagulation are excluded from

tients with systolic heart failure mandate aggressive

TMVR studies thus far.

pharmaceutical

therapy

before

and

after

valve

intervention.

FINAL CONSIDERATIONS AND RECOMMENDATIONS

The role of an expert TEER operator is becoming
more important in contemporary trials randomizing

We acknowledge that there are challenges to the

against MitraClip therapy. An expert opinion docu-

execution of an RCT with current-generation TMVR

ment has recently been published that outlines the

technologies. The clinical community may be reluc-

anatomical criteria for TEER suitability (11). This

tant to randomize patients because of the current

document was developed on the basis of a request of

requirement for transapical access (Table 3). As a

the US Food and Drug Administration to harmonize

complicating matter, the anatomical criteria used in

TEER suitability criteria across TMVR trials by various

determining TEER candidacy have uncertainty (11)

manufacturers. Whether the TMVR RCT component is

attributable to recent device iterations as well as

executed in a patient population that is suitable for

continued operator experience with the therapy,

TEER (Figure 2A) or not suitable for TEER (Figure 2B),

both of which have been shown to lead to greater

rigorous assessment of TEER suitability must be made

effectiveness and better safety (12). However, such

by the expert TEER operators of the subject eligibility

reluctance for either randomization or the choosing

committee on the basis of the published criteria (11).

of criteria for randomization are addressable with

At least 2 experienced TEER operators should vote on

study oversight and should not cause abandonment

TEER suitability to ensure that appropriate patients

of RCTs for the evaluation of TMVR technologies, as

are being enrolled. The subject eligibility committee

single-arm-only trials have major limitations. For

should review the transesophageal echocardiographic

example, even in a well-structured single-arm trial

studies along with quantitative assessment of the

with strong oversight, the subject eligibility commit-

transesophageal and transthoracic echocardiographic

tee may be at risk for selection “creep” by enrolling

studies by the echocardiography core laboratory to

patients with debatable anatomical criteria that are

determine TEER suitability and thereby determine

within TEER indications for use, if a TEER treatment

next steps for the trial. For the trial framework out-

arm within a concurrent RCT does not exist.

lined in Figure 2A, the subject eligibility committee

Although

TMVR

result

compared

in

longer

with

TEER

post-

procedural

domized arm (against TEER) or in one of the non-

require anticoagulation therapy, it is important to

randomized arms (for non-TEER patients). Similarly,

note that the safety proﬁle for some TMVR devices

for the trial framework outlined in Figure 2B, the

has been excellent, with long-term clinical outcomes

subject eligibility committee will determine eligibility

comparable with TEER registry data (13-15). As a

for the trial, as both the RCT and the single arms are

rapidly emerging ﬁeld, pivotal RCTs are needed to

in patients who are not suitable for TEER.

recovery

may

will determine whether the patient is in the ran-

and

study the risks and beneﬁt of MR elimination versus
MR reduction of TMVR versus TEER in patients with

ANTITHROMBOTIC THERAPY CONSIDERATIONS

MR, whether the etiology is simple or complex.
Furthermore, with emerging data on mitral thera-

Current guidelines (2) recommend antithrombotic

pies, stand-alone single-arm trials for novel TMVR

therapy with a vitamin K antagonist (warfarin) for the

therapies using performance goals as the sole basis

ﬁrst 3 to 6 months following surgical mitral valve

for evidence generation have limitations and are

replacement (Class 2A) to allow the endothelium to

most powerful when complemented with a concur-

cover the bioprosthetic material and minimize the

rent RCT to minimize patient selection bias and
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